检索结果 - Myron S. Czuczman

Refine Results
  1. 1
    Use of rituximab, the new FDA-approved antibody

    Use of rituximab, the new FDA-approved antibody 由 Gail A. Leget, Myron S. Czuczman

    出版 1998
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  2. 2
    Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression

    Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression 由 Scott H. Olejniczak, Francisco J. Hernandez‐Ilizaliturri, James L. Clements, Myron S. Czuczman

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up

    Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up 由 Myron S. Czuczman, Robin Weaver, Baha Alkuzweny, Judy Berlfein, Antonio J Grillo-López

    出版 2004
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma

    Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma 由 Ping‐Chiao Tsai, Francisco J. Hernandez‐Ilizaliturri, Naveen Bangia, Scott H. Olejniczak, Myron S. Czuczman

    出版 2012
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells <i>In Vitro</i> and in NSG Mice

    Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells <i>In Vitro</i> and in NSG Mice 由 Yaya Chu, Jessica Hochberg, Ashlin Yahr, Janet Ayello, Carmella van de Ven, Matthew J. Barth, Myron S. Czuczman, Mitchell S. Cairo

    出版 2014
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of rituximab <i>in vivo</i>

    Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of rituxima... 由 Nishitha Reddy, Francisco J. Hernandez‐Ilizaliturri, George Deeb, Mark S. Roth, Mary Vaughn, Joy Knight, Paul K. Wallace, Myron S. Czuczman

    出版 2007
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy

    Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy 由 Myron S. Czuczman, Christos Emmanouilides, Mohamed Darif, Thomas E. Witzig, Leo I. Gordon, Stephen Revell, Katie D. Vo, Arturo Molina

    出版 2007
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia

    Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-re... 由 Aradhana Awasthi, Janet Ayello, Carmella van de Ven, Mona Elmacken, Anthony Sabulski, Matthew J. Barth, Myron S. Czuczman, Humayun Islam, Christian Klein, Mitchell S. Cairo

    出版 2015
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

    Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody 由 David M. Goldenberg, Edmund A. Rossi, Rhona Stein, Thomas M. Cardillo, Myron S. Czuczman, Francisco J. Hernandez‐Ilizaliturri, Hans J. Hansen, Chien‐Hsing Chang

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Entinostat, a novel histone deacetylase inhibitor is active in B‐cell lymphoma and enhances the anti‐tumour activity of rituximab and chemotherapy agents

    Entinostat, a novel histone deacetylase inhibitor is active in B‐cell lymphoma and enhances the anti‐tumour activity of rituximab and chemotherapy agents 由 Sarah Frys, Zachary Simons, Qiang Hu, Matthew J. Barth, Juan Gu, Cory Mavis, Joseph J. Skitzki, Song Liu, Myron S. Czuczman, Francisco J. Hernandez‐Ilizaliturri

    出版 2015
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development

    Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development 由 Juan Gu, Anil Singh, Kai Xue, Cory Mavis, Matthew J. Barth, Vivek Yanamadala, Peter Lenz, Michael Grau, Georg Lenz, Myron S. Czuczman, Francisco J. Hernandez‐Ilizaliturri

    出版 2017
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Chemoimmunotherapy with ofatumumab in combination with <scp>CHOP</scp> in previously untreated follicular lymphoma

    Chemoimmunotherapy with ofatumumab in combination with <scp>CHOP</scp> in previously untreated follicular lymphoma 由 Myron S. Czuczman, Georg Heß, Ole Gadeberg, Lars Møller Pedersen, Nancy Goldstein, Ira Gupta, Roxanne C. Jewell, Thomas S. Lin, Steen Lisby, Claus Strange, Kristian Windfeld, Andreas Viardot

    出版 2012
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

    Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma 由 Kieron Dunleavy, Stefania Pittaluga, Myron S. Czuczman, Sandeep S. Davé, George W. Wright, Nicole Grant, Margaret Shovlin, Elaine S. Jaffe, John E. Janik, Louis M. Staudt, Wyndham H. Wilson

    出版 2009
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)

    Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance) 由 John P. Leonard, Sin‐Ho Jung, Jeffrey L. Johnson, Brandelyn N. Pitcher, Nancy L. Bartlett, Kristie A. Blum, Myron S. Czuczman, Jeffrey K. Giguere, Bruce D. Cheson

    出版 2015
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response

    Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response 由 Asher Chanan‐Khan, Kena C. Miller, David Lawrence, Swaminathan P. Iyer, Austin Miller, Francisco Hernandez‐Illatazurri, Myron S. Czuczman, Paul K. Wallace, Jerome B. Zeldis, Kelvin H. Lee

    出版 2010
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    Comparison of Referring and Final Pathology for Patients With Non-Hodgkin's Lymphoma in the National Comprehensive Cancer Network

    Comparison of Referring and Final Pathology for Patients With Non-Hodgkin's Lymphoma in the National Comprehensive Cancer Network 由 Ann S. LaCasce, Michelle E. Kho, Jonathan W. Friedberg, Joyce C. Niland, Gregory A. Abel, Maria Alma Rodriguez, Myron S. Czuczman, Michael Millenson, Andrew D. Zelenetz, Jane C. Weeks

    出版 2008
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma

    Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma 由 Brad S. Kahl, Nancy L. Bartlett, John P. Leonard, Ling Chen, Kristen N. Ganjoo, Michael E. Williams, Myron S. Czuczman, Katherine Robinson, Robin Joyce, Richard H. van der Jagt, Bruce D. Cheson

    出版 2009
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    Biological effects and clinical significance of lenalidomide‐induced tumour flare reaction in patients with chronic lymphocytic leukaemia: <i>in vivo</i> evidence of immune activation and antitumour response

    Biological effects and clinical significance of lenalidomide‐induced tumour flare reaction in patients with chronic lymphocytic leukaemia: <i>in vivo</i> evidence of immune activat... 由 Asher Chanan‐Khan, Kasyapa S. Chitta, Noreen Ersing, Aneel Paulus, Aisha Masood, Taimur Sher, Abhisek Swaika, Paul K. Wallace, Terry Mashtare, Greg Wilding, Kelvin H. Lee, Myron S. Czuczman, Ivan Borrello, Naveen Bangia

    出版 2011
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Diffuse Large B Cell Lymphoma: Update of the 2001 Evidence-Based Review

    The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Diffuse Large B Cell Lymphoma: Update of the 2001 Evidence-Based Review 由 Denise M Oliansky, Myron S. Czuczman, Richard I. Fisher, Frank D. Irwin, Hillard M. Lazarus, James Omel, Julie M. Vose, Steven N. Wolff, Roy B. Jones, Philip L. McCarthy, Theresa Hahn

    出版 2010
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  20. 20
    CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells

    CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells 由 Juan Du, Sandra López‐Vergès, Brandelyn N. Pitcher, Jeffrey L. Johnson, Sin‐Ho Jung, Lili Zhou, Katharine C. Hsu, Myron S. Czuczman, Bruce D. Cheson, Lawrence Kaplan, Lewis L. Lanier, Jeffrey M. Venstrom

    出版 2014
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: